Becton, Dickinson and Company $BDX Shares Sold by Korea Investment CORP

Key Points

• Korea Investment CORP cut its stake in Becton, Dickinson & Company by 53.1% in Q3, selling 68,659 shares and now holding 60,543 shares worth about $11.33 million.
• Becton, Dickinson beat quarterly estimates with EPS of $2.91 (vs. $2.81 expected) and $5.25 billion in revenue, and set FY2026 guidance of $12.35–$12.65 EPS.
• Analysts are mixed: the stock has a consensus rating of Hold with a consensus price target of $195.46 after several firms updated their targets and ratings.

Korea Investment CORP reduced its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 53.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,543 shares of the medical instruments supplier's stock after selling 68,659 shares during the period. Korea Investment CORP's holdings in Becton, Dickinson and Company were worth $11,332,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. SOA Wealth Advisors LLC. increased its position in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management boosted its stake in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 97 shares in the last quarter. Bell Investment Advisors Inc grew its holdings in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier's stock worth $27,000 after acquiring an additional 128 shares during the period. Cornerstone Planning Group LLC raised its position in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock worth $30,000 after acquiring an additional 139 shares in the last quarter. Finally, Accredited Wealth Management LLC lifted its holdings in Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 70 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on BDX shares. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, January 7th. Bank of America upped their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a "neutral" rating in a report on Monday, January 5th. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 2nd. Piper Sandler reaffirmed a "neutral" rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, TD Cowen upped their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a "hold" rating in a report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $195.46.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,416 shares of company stock valued at $674,693 over the last ninety days. Company insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $163.22 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The firm has a market capitalization of $46.47 billion, a price-to-earnings ratio of 26.63, a price-to-earnings-growth ratio of 11.88 and a beta of 0.24. The company has a 50 day simple moving average of $191.41 and a 200-day simple moving average of $190.50. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. During the same quarter in the prior year, the business earned $3.43 EPS. The company's revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company's dividend payout ratio is presently 68.52%.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase program on Tuesday, January 27th that authorizes the company to buyback $10.00 million in shares. This buyback authorization authorizes the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.